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Abstract: Colorectal cancer is a leading cause of cancer death worldwide. To identify molecular 
targets for colorectal cancer therapy, we tested small interfering RNAs (siRNAs) against 
97 genes whose expression was elevated in human colorectal cancer tissues for the ability to 
promote apoptosis of human colorectal cancer cells (HT-29 cells). The results indicate that the 
downregulation of PSMA7 (proteasome subunit, α-type, 7) and RAN (ras-related nuclear protein) 
most efficiently induced apoptosis of HT-29 cells. PSMA7 and RAN were highly expressed in 
colorectal cancer cell lines compared with normal colon tissues. Furthermore, PSMA7 and RAN 
were overexpressed in not only colon tumor tissues but also the other tumor tissues. Moreover, 
in vivo delivery of PSMA7 siRNA and RAN siRNA markedly induced apoptosis in HT-29 
xenograft tumors in mice. Thus, silencing of PSMA7 and RAN induces cancer cells to undergo 
apoptosis, and PSMA7 and RAN might be promising new molecular targets for drug and RNA 
interference-based therapeutics against colorectal cancer.
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Introduction
Colorectal cancer is one of the most common cancers in women and men worldwide. 
Nearly 1.2 million cases of colorectal cancer were expected to occur in 2007.1 The 
highest incidence rates are found in Japan, North America, parts of Europe, New Zealand, 
and Australia.1 Worldwide, some 630,000 people die from colorectal cancer per 
year, accounting for 8% of all cancer deaths.1 The five-year survival for persons with 
colorectal cancer is about 65% in Japan; however, when this cancer is detected at 
advanced stages, the five-year survival rate decreases to 10%,2 necessitating effective 
therapeutic targets.
A tumor is characterized by uncontrolled growth and spread of abnormal cells, which 
invade adjacent normal tissue and spread to other organs, a process that causes death.3 
Multiple molecular alterations are involved in a transformation from a normal cell into a 
cancerous cell and a progression from a pre-cancerous lesion to malignant tumors.
Angiogenesis is critical in tumor growth and survival. Its inhibition is a promising 
target for cancer therapy.4–6 Vascular endothelial growth factor (VEGF) plays a key 
role in angiogenesis in cancer. In many human tumors including colorectal cancer, 
VEGF amd VEGF receptors (VEGFR) are overexpressed. Regulating the VEGF/
VEGFR pathway is an effective approach to treat cancer.6,7 A humanized anti-VEGF 
monoclonal antibody, Bevacizumab, is the first approved biological inhibitor against 
VEGF for the treatment of metastatic colorectal cancer.4–6,8 Small-molecule tyrosine International Journal of General Medicine 2009:2 244
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kinase inhibitors against VEGFRs are also being developed 
for cancer therapy.4,6,9,10
Furthermore, the survival of abnormal cells is a charac-
teristic feature of cancer. In colorectal tumors, some signal 
transduction pathways drive abnormal cell growth. The most 
important factor promoting cell survival is epidermal growth 
factor (EGF).11,12 Its signaling is a potential target for cancer 
therapy.4,5 In treating colorectal cancer, a monoclonal anti-
body against EGF receptor (EGFR) such as a cetuximab is 
active,4,5,12–14 and small-molecular tyrosine kinase inhibitors 
of EGFRs have been shown to be effective.4,12
Additionally, one of the hallmarks of human carcino-
genesis is the breakdown of cell apoptotic machinery.15 
Overexpression of anti-apoptotic Bcl-2 family members 
frequently relates to decreased sensitivity to anticancer drugs 
and radiotherapy in many types of cancer.16 The antisense 
oligonucleotide drug targeting Bcl-2 mRNA expression 
such as an oblimersen is being investgated in some cancers.17 
The BH3-domain of anti-apoptotic Bcl-2 family proteins is 
required for the antiapoptotic function. BH-3 mimic pep-
tides that interfere with Bcl-2 signaling are currently under 
development.16 Moreover, therapies based on tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL), which 
induces programmed cell death, have been studied.18 Mono-
clonal antibodies against TRAIL receptors with an agonistic 
effect on the TRAIL pathway have been generated.18,19 Thus, 
inducing apoptosis is a promising approach in the develop-
ment of a molecular targeted therapy for cancer.
In this paper, we focused on apoptosis induction to identify 
molecular targets for colorectal cancer therapy. We tested 
siRNAs against 97 genes whose expression was elevated in 
human colorectal cancer tissues for the ability to promote 
apoptosis of human colon cancer cells (HT-29 cells). The 
results showed that the downregulation of proteasome subunit, 
α-type, 7 (PSMA7) and ras-related nuclear protein (RAN) 
strongly caused apoptosis of HT-29 cells. PSMA7 siRNA and 
RAN siRNA markedly induced apoptosis in HT-29 xenograft 
tumor tissues in mice. This silencing of PSMA7 and RAN that 
induces cancer cells to undergo apoptosis suggests that PSMA7 
and RAN are potential key targets for future RNA interference 
(RNAi)-based therapeutics against colorectal cancer.
Materials and methods
cell culture
Five colorectal cancer cell lines were obtained from the 
American Type Culture Collection (ATCC), and maintained 
at 37 °C under 5% CO2 in a humidified incubator. Caco-2 
(human colorectal adenocarcinoma) cells were cultured in 
Eagle’s minimum essential medium (EMEM; Invitrogen, 
Carlsbad, CA, USA) supplemented with 10% fetal bovine 
serum (FBS; Invitrogen) and nonessential amino acids 
(Invitrogen). Human colorectal carcinoma (HCT116) and 
human colorectal adenocarcinoma (HT-29) cells were cul-
tured in McCoy’s 5A medium (Invitrogen) containing 10% 
FBS. LoVo (human colorectal adenocarcinoma, derived 
from supraclavicular lymph node metastatic site) cells were 
cultured in Ham’s F12 medium (Invitrogen) containing 10% 
FBS. T84 (human colorectal carcinoma, derived from lung 
metastatic site) cells were cultured in DMEM/Ham’s F-12 
medium (Invitrogen) containing 10% FBS. To obtain total 
RNA from these cell lines we plated cells at 1 × 105 cells per 
well (6-well plate) and culture for three days.
Design and synthesis of siRnAs
We designed siRNAs and synthesized them with four siRNA 
duplexes for each gene target (Dharmacon, Chicago, IL, 
USA). The siRNA sequences were described in Table 1.
cell transfection array
For RNAi-based functional screening of genes, we used a 
reverse transfection based-cell transfection array.20 HT-29 
cells were plated into the cell transfection array in a 96-well 
format and transfected with siRNA. We evaluated the effects 
of the downregulation of genes on promotion of apoptosis, 
as mentioned below.
Measurement of cell proliferation
We plated HT-29 cells into a cell transfection array at a 
density of 5 × 103 cells per well and cultured. Three days 
after, we measured cell proliferation by resazurin reduction 
assay using CellTiter-Blue Reagent (Promega, Madison, WI, 
USA). Cells were incubated with CellTiter-Blue Reagent for 
one hour at 37 °C, and the fluorescence was then measured 
at 560Ex/590Em. After that, we subjected the same cell 
transfection array to a caspase-3/7 assay, Hoechst staining, 
and a cell-direct real-time reverse transcriptase-polymerase 
chain reaction (RT-PCR) assay.
Measurement of caspase activity in vitro
Cells were incubated with the Caspase-Glo 3/7 Reagent 
(Promega) for one hour at room temperature, and the lumi-
nescence was then measured.
Hoechst staining
Cells on a cell transfection array were washed with phosphate-
buffered saline (PBS), and a fixative and staining solution was International Journal of General Medicine 2009:2 245
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added (4% paraformaldehyde, 0.1% Triton X-100, 1 µg/mL 
Hoechst 33342 in PBS). Twenty minutes after incubation, 
cells were washed with PBS. We determined the number of 
apoptotic cells was in three microscopic fields of each well 
by fluorescence microscopy.
Transfection of siRnA
We carried out transfection of HT-29 cells with siRNA 
using Liopfectamine 2000 (Invitrogen), according to the 
manufacturer’s protocol. We plated HT-29 cells 24 hours 
before transfection, and we then transfected the cells, which 
were grown to 50% confluence, with 40 nM siRNAs.
Real-time RT-PcR
We purified total RNA from cells and tumor tissues with an 
RNeasy Mini Kit and RNase-Free DNase Set (QIAGEN, 
Hilden, Germany), and produced cDNAs with an ExScript 
RT reagent Kit (Takara Bio, Shiga, Japan). We then sub-
jected cDNA samples to real-time PCR using SYBR Pre-
mix Ex Taq (Takara) and specific primers as follows: for 
PSMA7, forward, 5´-CAAGTGGAGTACGCGCAGGA-3´; 
reverse, 5´-CTGCAGTTTGGCCACTGACTTC-3´; for 
RAN, forward, 5´-AAGTTGTCATGGACCCAGCTTTG-3´; 
reverse, 5´-GCTGGGCTCCAGCTTCATTC-3´. We carried 
out the reactions using the 7300 Real-Time PCR System 
(Applied Biosystems, Foster City, CA, USA). We normalized 
gene-expression levels by 18S rRNA or GAPDH.
cell-direct real-time RT-PcR
We used FastLane Cell cDNA Kit and QuantiTect SYBR 
Green PCR Kit (QIAGEN). We lysed cells in a well of cell 
transfection array and synthesized the first-strand cDNA. 
The cDNA template was then directly subjected to real-time 
RT-PCR using specific primers.
siRnA treatment in vivo
We performed animal experiments in compliance with the 
guidelines of the Institute for Laboratory Animal Research, 
National Cancer Center Research Institute of Japan. We 
subcutaneously injected 5 × 106 HT-29 cells into athymic 
nude mice (six-week-old females; CLEA Japan, Tokyo, 
Japan). When the HT-29 tumor grew to approximately 
5–6 mm in diameter, we injected mice with 1 nmol siRNA 
by intratumoral injection. We harvested tumor tissues for 
analysis of mRNA and apoptosis at 24 and 72 hours after 
treatment, respectively.
TUneL technique
We harvested tumor tissues 72 hours after administration 
of siRNA and prepared frozen sections. We then performed 
TUNEL (TdT-mediated dUTP nick-end labeling) stain-
ing using an In Situ Cell Death Detection Kit, Fluorescein 
(Roche Diagnostics, Basel, Switzerland), according to the 
manufacturer’s protocol. DNA strand breaks in apoptotic 
cells can be labeled by the addition of fluorescein dUTP 
using terminal deoxynucleotidyl transferase (TdT). The 
nuclei were stained with DAPI. We determined the number 
of fluorescein-positive cells in three microscopic fields of 
each section by fluorescence microscopy.
Human samples
The study protocol for clinical samples was approved by the 
Institutional Review Board of Osaka University Medical 
School (Osaka, Japan), and written informed consent was 
Table 1 The sequences of siRnAs
  Sense strand Antisense strand
PSMA7
#1 5´-GAAGUAUGUUGcUGAAAUUUU-3´ 5´-AAUUUcAGcAAcAUAcUUcUU-3´
#2 5´-GAAGAGAcAUUGUUGUUcUUU-3´ 5´-AGAAcAAcAAUGUcUcUUcUU-3´
#3 5´-GAAGAUcUGUGcUUUGGAUUU-3´ 5´-AUccAAAGcAcAGAUcUUcUU-3´
#4 5´-cAUcGUGGGUUUcGAcUUUUU-3´ 5´-AAAGUcGAAAcccAcGAUGUU-3´
RAN
#1 5´-AGAAGAAUcUUcAGUAcUAUU-3´ 5´-UAGUAcUGAAGAUUcUUcUUU-3´
#2 5´-GUGAAUUUGAGAAGAAGUAUU-3´ 5´-UAcUUcUUcUcAAAUUcAcUU-3´
#3 5´-ccUAUUAAGUUcAAUGUAUUU-3´ 5´-AUAcAUUGAAcUUAAUAGGUU-3´
#4 5´-AcAGGAAAGUGAAGGcGAAUU-3´ 5´-UUcGccUUcAcUUUccUGUUU-3´
Abbreviation: siRnA, small interfering RnAs.International Journal of General Medicine 2009:2 246
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obtained from each patient. We obtained total RNA from 
tumor tissues and normal adjacent tissues (FirstChoice 
Human Tumor/Normal Adjacent Tissue RNA) from Ambion 
(Austin, TX, USA).
cDnA micro-array analysis
We performed cDNA micro-array analysis using AceGene 
(DNA Chip Research Inc., Yokohama, Japan) according to 
the manufacturer’s instructions (http://www.dna-chip.co.jp/
thesis/AceGeneProtocol.pdf) to obtain an expression profile 
of human colorectal cancer.21 As a standard normal control 
reference, a mixture of total RNA extracted from normal 
colorectal tissues was used. We synthesized cDNA from 
total RNA of normal colorectal tissues and colorectal tumor 
tissues, and labeled cDNA with Cy3 for normal colorectal 
tissue, and Cy5 for colorectal tumor tissues, respectively. After 
hybridization of cDNA and array, the array was scanned, and 
Cy5/Cy3 ratios were log2-transformed to compare levels of 
mRNA expression in tumor and normal tissues.
statistical analysis
We conducted statistical analysis using the analysis of 
variance with Student’s t-test. We considered a P value of 
0.05 or less as a significant difference.
Results
RNAi-based screening for identification 
of molecular targets
To identify molecular targets for therapy, we conducted a 
study of RNAi-induced gene knockdown in HT-29 human 
colon cancer cells. The strategy for target identification is 
schematically shown in Figure 1. We performed gene expres-
sion profiling of 191 subjects with colorectal tumors and 
selected 97 genes whose expression was elevated in human 
colorectal cancer tissues by rank order of mRNA expression 
(Table 2). We used the siRNAs specific to these genes which 
are siRNA pools composed of four distinct siRNA species 
targeting different sequences of the same target transcript for 
RNAi-based screening. We transfected HT-29 cells with the 
Highly expressed genes 
Screening by reverse genetics (siRNA)
Cell transfection array
• Molecular target drug
• RNAi medicine
Colorectal tumor model
Induction of apoptosis
Validation of target molecule
Local delivery of siRNAs
Colorectal cancer
Gene expression profiling
Figure 1 Schematic representation of the strategy for targets identification by RNAi-based reverse genetics in vitro and in vivo. First, we carried out a gene expression profil-
ing of human colorectal tumor tissues and selected genes whose expression was elevated.   We performed a functional screening of genes by a cell transfection array to test 
the efficacy of a specific siRNA related to apoptosis induction in human colorectal cancer. Subsequently, the siRNAs against candidate genes were applied to an in vivo animal 
tumor model. Finally, we identified new molecular targets for drug and RNAi-based colorectal cancer therapy.
Abbreviation: siRnA, small interfering RnAs.International Journal of General Medicine 2009:2 247
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Table 2 The list of 97 genes elevated in human colorectal tumor tissues
No Gene Description Accession no. Log2 ratio 
(tumor/normal)
1 COL1A1 collagen, type I, α1 nM_000088 2.137
2 SPP1 secreted phosphoprotein 1 (osteopontin, bone 
sialoprotein I, early T-lymphocyte activation 1)
nM_000582 1.531
3 CCL20 chemokine (c-c motif) ligand 20 nM_004591 1.501
4 UBD Ubiquitin D nM_006398 1.392
5 TGFBI Transforming growth factor, β-induced, 68 kDa nM_000358 1.345
6 IFITM1 Interferon induced transmembrane 
protein 1 (9–27)
nM_003641 1.341
7 MMP12 Matrix metallopeptidase 12 (macrophage elastase) nM_002426 1.248
8 CEACAM6 carcinoembryonic antigen-related cell adhesion 
molecule 6 (non-specific cross reacting antigen)
nM_002483 1.237
9 RPS21 Ribosomal protein s21 nM_001024 1.232
10 PFDN4 Prefoldin 4 nM_002623 1.209
11 TIMP1 TIMP metallopeptidase inhibitor 1 nM_003254 1.191
12 NEK6 nIMA (never in mitosis gene a)-related kinase 6 nM_014397 1.089
13 MMP1 Matrix metallopeptidase 1 (interstitial collagenase) nM_002421 1.079
14 S100A11 s100 calcium binding protein A11 (calgizzarin) nM_005620 1.055
15 IFNAR1 Interferon (α, β and ω) receptor 1 nM_000629 1.031
16 CPSF4 Cleavage and polyadenylation specific factor  
4, 30 kDa
nM_006693 1.024
17 TMEPAI Transmembrane, prostate androgen induced RnA nM_020182 1.013
18 RPL31 Ribosomal protein L31 nM_000993 0.995
19 CPNE3 copine III nM_003909 0.988
20 UBE2C Ubiquitin-conjugating enzyme e2c nM_007019 0.979
21 NQO1 nAD(P)H dehydrogenase, quinone 1 nM_000903 0.968
22 MYC V-myc myelocytomatosis viral oncogene 
homolog (avian)
nM_002467 0.966
23 LCN2 Lipocalin 2 (oncogene 24p3) nM_005564 0.959
24 PRKAA1 Protein kinase,   AMP-activated, α1 catalytic subunit nM_006251 0.958
25 GNGT2 Guanine nucleotide binding protein (G protein), 
gamma transducing activity polypeptide 2
nM_031498 0.932
26 PSMA7 Proteasome (prosome, macropain) subunit, 
α-type, 7
nM_002792 0.932
27 SLC3A2 solute carrier family 3 (activators of dibasic 
and neutral amino acid transport), member 2
nM_002394 0.925
28 C10ORF137 chromosome 10 open reading frame 137 nM_015608 0.917
29 CKS2 cDc28 protein kinase regulatory subunit 2 nM_001827 0.912
30 RPS6 Ribosomal protein s6 nM_001010 0.911
31 RPL39 Ribosomal protein L39 nM_001000 0.910
32 COL10A1 collagen, type X, α1(schmid metaphyseal 
chondrodysplasia)
nM_000493 0.910
33 MLLT1 Myeloid/lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila); translocated to, 1
nM_005934 0.896
34 GABRD γ-aminobutyric acid (GABA) A receptor, δ nM_000815 0.895
35 COL1A2 collagen, type I, α2 nM_000089 0.894
36 DKFZP564O0463 WD repeats and sOF1 domain containing nM_015420 0.894
37 RIPK2 Receptor-interacting serine-threonine kinase 2 nM_003821 0.893
(Continued)International Journal of General Medicine 2009:2 248
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Table 2 (Continued)
No Gene Description Accession no. Log2 ratio 
(tumor/normal)
38 FOXM1 Forkhead box M1 nM_021953 0.892
39 PIGL Phosphatidylinositol glycan, class L nM_004278 0.870
40 NIN ninein (GsK3B interacting protein) nM_016350 0.870
41 ATP2B1 ATPase, ca++ transporting, plasma membrane 1 nM_001682 0.870
42 MIF Macrophage migration inhibitory factor 
(glycosylation-inhibiting factor)
nM_002415 0.861
43 PCYOX1 Prenylcysteine oxidase 1 nM_016297 0.850
44 ARF4 ADP-ribosylation factor 4 nM_001660 0.843
45 MEOX2 Mesenchyme homeo box 2  
(growth arrest-specific homeo box)
nM_005924 0.840
46 HTR2B 5-hydroxytryptamine (serotonin) receptor 2B nM_000867 0.836
47 HRASLS3 HRAs-like suppressor 3 nM_007069 0.827
48 GYPA Glycophorin A (includes ss blood group) nM_002099 0.819
49 GDF15 Growth differentiation factor 15 nM_004864 0.817
50 NPHS2 nephrosis 2, idiopathic, steroid-resistant (podocin) nM_014625 0.816
51 FIBL-6 Hemicentin 1 nM_031935 0.804
52 AKAP8L A kinase (PRKA) anchor protein 8-like nM_014371 0.787
53 SLC12A2 solute carrier family 12 (sodium/potassium/
chloride transporters), member 2
nM_001046 0.784
54 CDK10 cyclin-dependent kinase (cDc2-like) 10 nM_003674 0.781
55 UFM1 Ubiquitin-fold modifier 1 nM_016617 0.780
56 TBX19 T-box 19 nM_005149 0.775
57 DPEP1 Dipeptidase 1 (renal) nM_004413 0.775
58 NNMT nicotinamide n-methyltransferase nM_006169 0.754
59 RPS20 Ribosomal protein s20 nM_001023 0.748
60 ZNF84 Zinc finger protein 84 (hpf2); znf84 nM_003428 0.740
61 HIG2 Hypoxia-inducible protein 2 nM_013332 0.639
62 SNAI2 snail homolog 2 (Drosophila) nM_003068 0.610
63 SLAMF7 sLAM family member 7 nM_021181 0.604
64 RAN RAn, member RAs oncogene family nM_006325 0.603
65 SNAI1 snail homolog 1 (Drosophila) nM_005985 0.580
66 MRAS Muscle RAs oncogene homolog nM_012219 0.543
67 ARHGEF4 Rho guanine nucleotide exchange factor (GeF) 4 nM_015320 0.536
68 MDK midkine (neurite growth-promoting factor 2) nM_002391 0.530
69 BRAF Y-raf murine sarcoma viral oncogene homolog B1 nM_004333 0.528
70 FBXO11 F-box protein 11 nM_012167 0.519
71 AATF Apoptosis antagonizing transcription factor nM_012138 0.516
72 FIGN Fidgetin nM_018086 0.506
73 MMP9 Matrix metallopeptidase 9 (gelatinase B, 92kDa 
gelatinase, 92kDa type IV collagenase)
nM_004994 0.497
74 VEGFA Vascular endothelial growth factor nM_003376 0.496
75 FBXW5 F-box and WD-40 domain protein 5 nM_178225 0.481
76 LTA Lymphotoxin α (TnF superfamily, member 1) nM_000595 0.476
77 TRAP1 TnF receptor-associated protein 1 nM_016292 0.455
78 LGALS1 Lectin, galactoside-binding, soluble, 1 (galectin 1) nM_002305 0.453
79 RRAS Related RAs viral (r-ras) oncogene homolog nM_006270 0.441
80 MMP10 Matrix metallopeptidase 10 (stromelysin 2) nM_002425 0.440
(Continued)International Journal of General Medicine 2009:2 249
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siRNAs using reverse transfection-based cell transfection 
array. To evaluate the efficiency of the cell transfection array, 
we used GAPDH siRNA against the gene encoding GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase). GAPDH 
siRNA transfer caused an approximate 75% reduction of 
the GAPDH mRNA expression in HT-29 cells relative to the 
control nontargeting siRNA (data not shown).
We assessed siRNAs for their ability to induce apoptosis 
in HT-29 compared with the control nontargeting siRNA. We 
measured cell viability by resazurin reduction and examined 
apoptosis by caspase-3/7 activity. Caspase-3/7 activity was 
normalized by viable cell number (measurement value of 
resazurin reduction) and Caspase-3/7 activation by siRNAs 
was compared with control nontargeting siRNA. The results 
indicated that the downregulation of 11 genes (TIMP1, 
S100A11, TMEPAI, PSMA7, COL10A1, RAN, VEGFA, LTA, 
TRAP1, MMP10, and RHEB) resulted in a marked induction 
of apoptosis in HT-29 cells (caspase-3/7 activity, percentage of 
nontargeting siRNA  200, P  0.05, Figure 2). In particular, 
the PSMA7 siRNA pool and the RAN siRNA pool strongly 
enhanced caspase-3/7 activity (caspase-3/7 activity, percent-
age of nontargeting siRNA  300, P  0.001, Figure 2). 
We validated these results by counting Hoechst-stained cells 
showing apoptotic nuclear condensation and fragmentation 
(Figure 3A) and found that there was a significantly higher 
apoptotic cell death rate in cells given PSMA7 siRNA pool 
and RAN siRNA pool relative to that in cells given control 
siRNA (P  0.01, Figure 3B). At 72 hours after treatment 
with siRNA, there was substantial cell death induced by the 
PSMA7 siRNA pool and the RAN siRNA pool compared 
with the control nontargeting siRNA (Figure 3C).
We assessed the efficacy of PSMA7 siRNA pool and 
RAN siRNA pool for the knockdown of mRNA by cell-
direct real-time RT-PCR analysis. This analysis revealed 
that PSMA7 siRNA pool and RAN siRNA pool inhibited 
the mRNA expression relative to the control nontargeting 
siRNA, 80% and 60% respectively (Figure 3D). To evaluate 
the knockdown efficiency of individual siRNAs of the siRNA 
pool, we performed a liposome-mediated siRNA transfec-
tion. PSMA7 siRNA #2 and RAN siRNA #4 most efficiently 
silenced PSMA expression (70% reduction of mRNA) and 
RAN expression (70% reduction of mRNA), respectively 
(Figure 3E). We also confirmed that PSMA7 siRNA #2 and 
RAN siRNA #4 strongly increased caspase-3/7 activity in 
HT-29 cells (data not shown). PSMA7 siRNA #2 and RAN 
siRNA #4 were used in further in vivo experiments.
Table 2 (Continued)
No Gene Description Accession no. Log2 ratio 
(tumor/normal)
81 FBXW11 F-box and WD-40 domain protein 11 nM_012300 0.440
82 SAT spermidine/spermine n1-acetyltransferase nM_002970 0.440
83 RPN2 Ribophorin II nM_002951 0.400
84 RAB4B RAB4B, member RAs oncogene family nM_016154 0.398
85 FETUB Fetuin B nM_014375 0.395
86 ELF4 e74-like factor 4 (ets domain transcription factor) nM_001421 0.388
87 SHAX3 chromatin modifying protein 4c nM_152284 0.387
88 ECT2 epithelial cell transforming sequence 2 oncogene nM_018098 0.384
89 HES6 Hairy and enhancer of split 6 (Drosophila) nM_018645 0.383
90 DDEF1 Development and differentiation enhancing  
factor 1
nM_018482 0.378
91 RHEB Ras homolog enriched in brain nM_005614 0.375
92 CTNND1 catenin (cadherin-associated protein), δ1 nM_001331 0.368
93 DNMT3B DnA (cytosine-5-)-methyltransferase 3β nM_006892 0.365
94 ASPM AsP (abnormal spindle)-like, microcephaly  
associated (Drosophila)
nM_018136 0.360
95 PCDHA10 Protocadherin α10 nM_018901 0.349
96 VEGFC Vascular endothelial growth factor c nM_005429 0.347
97 RASGRF1 Ras protein-specific guanine nucleotide-releasing 
factor 1
nM_002891 0.346International Journal of General Medicine 2009:2 250
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Thus, downregulation of PSMA7 and RAN expression by 
siRNA induces apoptosis in colon cancer cells, results that 
suggest that PSMA7 and RAN might act as a suppressor of 
apoptosis in colorectal cancer.
Overexpression of PsMA and RAn in 
colorectal cancer cell lines and tumor tissues
To investigate the role of PSMA and RAN in colorectal 
cancer, we analyzed the mRNA expression levels of PSMA7 
and RAN by real-time RT-PCR. PSMA7 and RAN mRNA 
were significantly highly expressed in colorectal cancer cell 
lines Caco-2 (human colorectal adenocarcinoma), HCT116 
(human colorectal carcinoma), HT-29 (human colorectal 
adenocarcinoma), LoVo (human colorectal adenocarcinoma, 
derived from supraclavicular lymph node metastatic site) 
and T84 (human colorectal carcinoma, derived from lung 
metastatic site), compared with normal colon tissues 
(Figures 4A, 4B). mRNA expression levels of PSMA7 
and RAN in human tumoral colon tissues were higher than 
those of normal adjacent colon tissues (Figures 4C, 4D). 
These results indicate that PSMA7 and RAN strongly 
correlated with colorectal tumorigenesis and malignancy.
Furthermore, PSMA7 was overexpressed in other tumor 
tissues, especially uterus, stomach, and small intestine tumor 
tissues (Figure 4C). Similarly, RAN was overexpressed in 
other tumor tissues, in particular uterus, liver, testis, and stom-
ach tumors and lymphoma tissues (Figure 4D). Thus, PSMA7 
and RAN were overexpressed in not only colon tumor tissues 
but also in other tumor tissues, and PSMA7 and RAN might 
be involved in the development of multiple cancers.
correlation of PsMA7 and RAn 
expression with liver and lung metastases 
in human colorectal cancer
We next investigated the levels of PSMA7 and RAN expression 
in human colorectal cancers. The results are summarized in 
Table 3. PSMA7 showed a borderline significance (P = 0.076) 
for correlation with liver metastasis in colorectal cancer 
patients. In contrast, no significant correlation between 
the PSMA7 expression and lung metastasis was found in 
patients (P = 0.534). Decreased expression of RAN showed a 
significance (P = 0.023) for correlation with lung metastasis; 
however, there is no correlation with liver metastasis 
(P = 0.911). However, to know whether or not the levels of 
PSMA7 and RAN expression showed correlation with any 
other clinicopathological features such as depth of invasion, 
tumor size, lymphatic invasion, or the presence of lymph 
node metastasis, further analysis is needed.
PsMA7 siRnA and RAn siRnA induce 
apoptosis in vivo
To extend our in vitro findings and to determine whether 
PSMA7 and RAN could be effective therapeutic targets 
for colorectal cancer, we examined the effect of PSMA7 
siRNA and RAN siRNA on an animal model of colon 
tumors by subcutaneously implanting HT-29 cells into mice. 
We injected the PSMA7 siRNA #2, RAN siRNA #4, or 
nontargeting control siRNA (1 nmol per tumor) into tumors 
that had reached 5–6 mm in diameter seven days after 
inoculation of HT-29 cells. The mRNA levels of PSMA7 
and RAN in the tumors given siRNA were measured. mRNA 
expression was significantly reduced in mouse tumors 
24 hours after treatment with PSMA7 siRNA and RAN 
siRNA, 40% and 30% reduction relative to nontargeting 
control siRNA, respectively (P  0.05, Figure 5A).
HT-29 tumors treated with PSMA7 siRNA or RAN 
siRNA were investigated for apoptotic activity. Three days 
after siRNA treatment, we performed TUNEL staining which 
detects apoptotic DNA breaks in situ. TUNEL staining of 
tumor tissue treated with PSMA7 siRNA and RAN siRNA 
revealed a significant number of apoptotic cells relative to 
the number in the nontargeting control siRNA treated tumors 
Table 3 correlation of PSMA7 and RAN expression with liver and lung metastases in human colorectal cancer
No of subjects PSMA7 RAN
(n = 191) expression P-value expression P-value
Liver metastasis
  Positive 41 1.108 ± 0.116
0.0762
0.597 ± 0.052
0.9112
  negative 150 0.884 ± 0.043 0.605 ± 0.031
Lung metastasis
  Positive 29 0.870 ± 0.112
0.5336
0.460 ± 0.064
0.0233
  negative 162 0.943 ± 0.045 0.629 ± 0.029
Note:   Values are mean ± standard error.International Journal of General Medicine 2009:2 254
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(P  0.05, Figures 5B, 5C). These results indicate that PSMA7 
siRNA and RAN siRNA induce apoptotic cell death in vivo.
Discussion
Molecular targeted therapy is one of the most promising 
approaches in cancer treatment. For cancer researchers it is 
now possible to understand the molecular mechanisms of the 
development and progression in many types of cancer. It is 
expected that many potential new molecular targets will be 
discovered for cancer therapy. To identify molecular targets for 
colorectal cancer therapy, we performed a sophisticated strat-
egy using RNAi-based reverse genetics in vitro and in vivo. 
RNAi is a cellular mechanism for silencing of gene expression. 
Following the demonstration of RNAi mediated by siRNA in 
mammalian cells in 2001,22 RNAi has provided new powerful 
tools for biological research and drug discovery. Additionally, 
therapeutics based on RNAi offers a new class of pharmaceuti-
cal drugs. The inhibition of gene expression through RNAi 
is applicable to all classes of molecular targets, including the 
“undruggable targets” of traditional pharmaceutical drugs 
such as small molecule and protein.
First, we carried out a gene expression profiling of sub-
jects with colorectal tumors and selected 97 genes whose 
expression was elevated in human colorectal cancer tissues 
as a screening source of molecular targets. This starting 
from human disease samples has a great advantage, because 
cultured cells and disease models cannot faithfully repro-
duce the pathology of cancer. We then analyzed the function 
of genes using RNAi in vitro and in vivo. We performed a 
functional screening of genes by a reverse transfection-based 
cell transfection array to obtain an unbiased evaluation on 
the efficacy of a specific siRNA related to apoptosis induction 
in human colorectal cancer. An unbiased evaluation is 
important in the discovery of a new and unique target that 
brings a novel concept of targeted therapy. Our results showed 
that the siRNA designed for PSMA7 and RAN significantly 
promoted apoptosis of HT-29 human colon cancer cells. 
In our next step, we demonstrated in vivo proof-of-concept 
by the administration of siRNA to a colon tumor model. The 
in vivo delivery of PSMA7 siRNA and RAN siRNA mark-
edly induced apoptosis in HT-29 tumors in mice. Finally, we 
identified PSMA7 and RAN as new molecular targets for an 
RNAi-based colorectal cancer therapy.
PSMA7 (also known as XAPC7) is a proteasome subunit.23 
The 26S proteasome consist of a 20S proteasome core and 
two 19S regulatory subunits.24 The 20S proteasome core 
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is a barrel-shaped structure arranged in four stacked rings. 
Of these four rings, two end rings are composed of seven 
α-subunits, and two central rings are composed of seven 
β-subunits. PSMA7 is one of the seven proteasome α-subunits 
of 20S proteasome. PSMA7 interacts specifically with 
hepatitis B virus X protein (HBX), which is important in the 
life cycle of the hepatitis B virus (HBV).25 In addition, PSMA7 
has a principal role in regulating activity of the hepatitis C 
virus (HCV) internal ribosome entry site (IRES), a function 
essential for HCV replication.26
The ubiquitin–proteasome pathway is the main extra-
lysosomal system involved in intracellular proteolysis and 
is critical for the proliferation and survival of all cells.24,27 In 
particular cancerous cells, the ubiquitin-proteasome pathway 
plays an integral role in the mechanisms underlying carci-
nogenesis and metastasis, including cell cycle regulation, 
apoptosis, and angiogenesis.24,27 The cancer cells exploit the 
proteasome for their own proliferation through the cell cycle 
by degrading of cell cycle regulatory proteins. Furthermore, 
the proteasome regulates apoptotic activity via effects on 
the pro-oncogenic nuclear factor (NF)-κB pathway, which 
is a transcriptional activator and activated in many types of 
tumor.28 Under normal conditions, NF-κB is bound to its 
inhibitor IκB (IκB) and in an inactive state. The proteasome 
degrades IκB in response to cellular stresses, and then 
NF-κB activates transcription of genes for growth factors 
and apoptosis inhibitors.24,29,30 Therefore, proteasome is an 
attractive target for cancer therapy. A dipeptidyl boronic acid 
proteasome inhibitor, bortezomib, suppresses degradation 
of IκB by proteasome and blocks NF-kB signaling with 
resultant apoptosis.24,27,29 The efficacy of bortezomib is inves-
tigated in various types of malignancies including advanced 
colorectal cancer.24,31,32 However, the ubiquitin-proteasome 
pathway is essential for maintenance of cell function in all 
cells, and the proteasome inhibitor may attack normal cells 
and cause severe side effects in patients.33,34 A proteasome 
inhibitor specific for cancer cells should provide a better 
treatment with minimal side effects. In this study, among 
proteasome subunits genes, PSMA7 is the only gene listed 
for genes whose expression is elevated in human colorectal 
cancer tissues. RNAi-mediated specific inhibition of PSMA7 
may be a smart colorectal cancer therapy. Although it is 
impossible at the moment to judge whether PSMA7 silencing 
inhibited degradation of IκB by proteasome and blocks 
NF-kB signaling, in fact, our results indicated that PSMA7 
siRNA caused apoptosis in HT-29 colon cells and HT-29 
tumor tissues. PSMA7 was overexpressed in not only colon 
tumor tissues but also in other tumor tissues, which suggests 
that PSMA7 might be a potential target against various types 
of cancer.
Moreover, PSMA7 is interesting because of the cor-
relation between its expression and the liver metastasis 
of colorectal cancer. Our study showed that expression of 
PSMA7 mRNA was elevated in colorectal tumor tissues 
from subjects with liver metastasis, although no statistical 
significance was found. Another research group also reported 
that overexpression of PSMA7 protein associates with 
liver metastasis in colorectal cancer.35 PSMA7 may be a 
predictive marker and a molecular target for liver metastasis 
from colorectal cancer. Further investigations are needed 
to confirm the relationship between PSMA7 and colorectal 
cancer liver metastasis by gene expression profiling on a 
validation set of colorectal cancer subjects and analysis of 
PSMA7 expression on a colorectal cancer liver metastatic 
site at both the mRNA and protein levels.
RAN protein (Ran) is a small GTPase belonging to the 
Ras superfamily. Ran is essential for the translocation of 
RNA and proteins through the nuclear pore complex.36,37 
GTPase Ran regulates numerous cellular processes by 
switching between a GTP-bound and GDP-bound form.38 
Ran is also critical for the regulation of the cell cycle through 
mitotic spindle assembly and post-mitotic nuclear envelope 
assembly.38,39
It is reported that Ran is a suppressor of Bcl-2-associated 
X protein (Bax), a pro-apoptotic member of the Bcl-2 family 
of proteins, and that it inhibits apoptosis induced by the 
anticancer drug paclitaxel.40 Furthermore, it is indicated that 
silencing of Ran in various tumor cell types causes aberrant 
mitotic spindle formation, mitochondrial dysfunction, 
and apoptosis.41,42 Ran is abundantly expressed in most 
cancer cell lines and cancer tissues.41 This suggests that 
Ran is associated with malignant transformation and/or the 
enhanced proliferation of cancer cells. There is a current 
finding that most tumor cells, but not normal tissues, become 
dependent on Ran signaling for cell mitosis.41 Targeting the 
Ran signaling pathway may provide a selective anticancer 
strategy.
This study showed that RAN mRNA was elevated in 
colon cancer cell lines and tissues, and in some types of tumor 
tissue. RAN silencing using RAN siRNA induced apoptosis 
in HT-29 colon cancer cells and HT-29 tumor tissues. RAN 
siRNA can specifically inhibit Ran which is a main molecule 
of RAN signaling, and may be a selective inhibitor against 
colon cancer.
We identified PSMA7 and RAN as new molecular 
targets for colorectal cancer therapy using RNAi-based International Journal of General Medicine 2009:2 256
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screening in vitro and in vivo. In a further study, we are 
investigating the antitumor activity of PSMA7 siRNA and 
RAN siRNA in a colon cancer model and a colon cancer 
liver metastasis model. Induction of apoptosis is one of the 
main targets for cancer therapy. The inhibitors of PSMA7 
and RAN may provide unique anticancer strategies based 
on novel mechanisms of action. Since the inhibition of gene 
expression through RNAi is highly specific and applicable 
to “undruggable targets”, RNAi-based therapeutics using 
PSMA7 siRNA and RAN siRNA is a particularly promising 
approach for cancer treatment.
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